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Abstract
Introduction
Obesity is the principal component in the Metabolic Syndrome (MetS) that determines the pro-
gression of metabolic complications. Metabolically healthy obese (MHO) individuals seem to be
protected against those complications. Telomere length (TL) as a novel marker of cellular aging
had a complex relationship to the MetS. The principal aim of this study was to investigate the TL
in MHO, and to study the association between TL and the worsening of the metabolic condition.
Material and methods
We have determined the absolute TL (aTL) in 400 women (mean age of 46.76 ± 15.47
years; range: 18–86 years), grouped according to the metabolic condition in three groups:
metabolically healthy non-obese women (MHNO), MHO and obese women with MetS
(MSO); and grouped according to the number of components of MetS.
Results
We found that MHO displays significantly higher aTL than MSO (p = 0.033; r = -4.63; 95%
CI r = -8.89 / -0.37), but did not differ from MHNO. A decrease in aTL with the progressive
increase in the number of MetS components was also observed (p < 0.001; r = -2.06; 95%
CI r = -3.13 / -0.99). In this way, our results indicate that aTL is influenced by the presence of
MetS, but it is not affected by the presence of obesity.
Discussion
We found that shorter aTL is not associated with MHO, but is related to MetS and with the
increased number of metabolic abnormalities.
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Introduction
The Metabolic Syndrome (MetS) is a cluster of cardiovascular and metabolic risk factors
including central obesity, hypertension, hyperglycemia and dyslipidemia. These well-known
risk factors co-segregate in an individual more often than might be expected by chance, and
predispose to type 2 diabetes mellitus and to cardiovascular disease (CVD). The etiology of
MetS is not yet well understood, but predisposing factors include aging, inflammation, obesity,
sedentary, lifestyle and genetics [1]. The insulin resistance is likely to be a significant link
between the components of MetS. Increased oxidative stress and inflammation have emerged
as playing a central role in MetS and may be a unifying factor in the progression of this disease.
Central obesity is the principal component of the MetS that determinates the progression of
those metabolic complications. However, a subgroup of obese individuals seems to be pro-
tected against obesity-related metabolic complications [2]. These individuals are described as
metabolically healthy obese (MHO), or as having uncomplicated obesity [3]. It is a new con-
cept in which an individual may exhibit an obese phenotype without the presence of MetS.
The existence of MHO phenotype was first proposed by Sims in 2001; it is considered that a
proportion between 15% and 20% of obese individuals may be free of metabolic complications
during an unknown period of time [4]. The subjects with MHO do not exhibit at baseline an
increased mortality, or an increased risk of CVD or type 2 diabetes compared to normal-
weight controls [5].
Telomere length (TL), generally assessed in leukocytes, is a novel marker of cellular aging
and has been associated with increased risks of morbidity and mortality [6,7]. Telomeres are
nucleoprotein complexes located at the ends of eukaryotic chromosomes, composed of DNA
tandem repeats (TTAGGG in mammals) and associated proteins. They play an essential role
in preserving chromosomal integrity and stability, constituting a critical factor in cell survival
[8]. Telomeric DNA erodes with each cell division by incomplete replication of the lagging
strand during DNA synthesis, known as the “end-replication problem”. Through this process,
each telomeric end shortens by approximately 20–60 base pairs (bp)/year in peripheral blood
lymphocytes [9–11]. In vitro studies have found that when telomeres become critically short,
cells stop dividing and promote replicative senescence, contributing to ageing and subsequent
somatic cells death [12]. Cellular damage due to increased oxidative stress [13] can further
accelerate the process of TL reduction. Therefore, TL can be considered as a biomarker of
aging, where shorter TL would indicate increased biological age. Indeed, metabolic disorders
such as MetS, which is aging related, display functional decline in tissues such as the heart,
liver and pancreas that are well-recognized features in aged individuals [14,15]. Some studies
have shown significant associations between shorter TL and central adiposity [16]. In this way,
the TL was shorter according to the worsening of the metabolic condition in a representative
sample of females [17]. It is known that there is a complex relationship between TL with obe-
sity and the MetS components, but we do not know the impact of the TL in particular groups
of obesity such as MHO. In this context, the principal aim of this study was to investigate the
absolute TL (aTL) in MHO individuals, who were compared with a control group composed
of non-obese individuals without MetS and with a cohort of patients with obesity and MetS.
Material and methods
Population
From the general population of Venado Tuerto, Province of Santa Fe, 1098 adult individuals
of both sexes were selected randomly in 2011 following a stratified multistage sampling design,
in accordance to the latest population census performed in 2010. Of the total population, 637
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individuals agreed to participate in the study, and we carried out this work only in women
(n = 400) taking into account gender differences in aTL [18,19]. The study was approved by
the Ethics Committee of Venado Tuerto Hospital and all participants gave their written
informed consent. The prevalence of chronic metabolic diseases and the study of biochemical
markers associated with CVD in the population are already published [20]. MHO group was
defined as individuals with obesity but without MetS [21]. For the diagnosis of obesity, body
mass index (BMI) 30 kg / m2 was considered. The diagnosis of MetS was performed accord-
ing to the ATPIII criteria [22], as individuals with three or more of the following components
for women: waist circumference 88 cm; fasting plasma glucose (FPG) 100 mg dl-1 or indi-
vidual treated for type 2 diabetes; systolic blood pressure (SBP) 130 mmHg / diastolic blood
pressure (DBP) 85 mmHg or individual treated for hypertension; high-density lipoprotein
cholesterol (HDL-C) < 50 mg dl-1 and triglycerides (TG) 150 mg dl-1 or individual treated
for dyslipidemia. For aTL study, MHO women were compared with two other groups: obese
women with MetS (MSO), a group with worse metabolic condition, consisting of individuals
with both MetS and obesity; and metabolically healthy non-obese women (MHNO), a group
with better metabolic condition, composed of individuals without obesity and MetS. In addi-
tion, we regrouped our population based on the number of components of MetS, into groups
of individuals without any component of MetS (0), with one component (1), two components
(2) and MetS with three or more components.
As TL was reported to be associated with the level of physical activity [23] and the lifetime
accumulated exposure to tobacco [24], all subjects completed a questionnaire detailing their
self-reported physical activity and cigarette smoking habits. It was considered the physical
activity level during leisure time and at work, and it was classified into 3 categories, where 1
indicates inactive; 2, light to moderate activity; and 3, heavy activity. To measure the exposure
to tobacco, pack-years smoked were calculated as the number of packs (20 cigarettes) smoked
per day multiplied by years of smoking.
Anthropometric measurements (height, weight and waist circumference), and SBP and
DBP were determined by a standardized protocol. BMI was calculated as weight (kg) /
[height (m)]2. After a 12 h overnight fast, venous blood samples (20 mL) were drawn in
every individual. One aliquot of blood was frozen at -20˚C and reserved for DNA extrac-
tion. The remaining aliquot was centrifuged to obtain serum and analyzed immediately.
FPG was determined by a glucose-oxidase method (GLU Glucose GOD-PAP, Roche Diag-
nostics, Mannheim, Germany) in a Hitachi 727 auto-analyzer. Fasting serum insulin (FSI)
was measured by electrochemiluminescence immunoassay with a commercial kit (Insulin,
Roche Diagnostics, Mannheim, Germany) in a Cobas e411 (Roche Diagnostics, Mann-
heim, Germany), with a lower detection limit of 2 μU/mL. As an indicator of insulinresis-
tance we used the homoeostasis model assessment (HOMA), calculated as FPG (mM)  FSI
(mIU/L) / 22.5. TG and HDL-C were determined in serum using standardized procedures
by enzymatic methods using commercial kits (TG Triglycerides GPO-PAP, and Phospho-
tungstate Precipitant and CHOL Cholesterol CHOD-PAP, Roche Diagnostics, Mannheim,
Germany) by using a Hitachi 727 auto-analyzer. Intra-CV (coefficient of variation) for TG
and HDL-C were 1.3% and 1.1%, respectively. Inter-CVs were 2.4% and 1.5%, respectively.
Serum high-sensitivity C reactive protein (hs-CRP) levels were measured using particle
enhanced immunonephelometry assay (Cardio Phase1 hsCRP, Siemens) on a Siemens BN
Prospect Nephelometer (Siemens Healthcare Diagnostics, Deerfield, IL, USA). We consid-
ered that hs-CRP values >10 mg/l were likely to represent an acute inflammatory response
in line with previous studies [25].
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Measurement of absolute TL
We carried out the aTL measurement by qPCR as previously described [26], in a LightCycler
system (Roche Diagnostics, Mannheim, Germany), which was previously validated by our
working group [27]. Genomic DNA was extracted from peripheral blood leucocytes. For each
DNA sample, two consecutive reactions were performed: the first one to amplify a fragment of
75 bp of the single copy gene RPLPO (ribosomal protein, large, PO), and the second one for
the telomeric sequence. Primers sequences for RPLPO PCR were 5’-CAGCAAGTGGGAAGG
TGTAATCC-3' (forward), and 5’-CCCATTCTATCATCAACGGGTACAA-3' (reverse); and
for the telomere PCR were 5’-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3'
(forward), and 5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCAATCCCT-3' (reverse).
Both PCRs were performed in a final volume of 20 μl containing 20 ng DNA, 1X SYBR Green
Master Mix (Roche Diagnostics, Mannheim, Germany) and 250 nM RPLPO primers or 100
nM telomere primers. The PCR conditions were: 10 min at 95˚C, followed by 45 cycles of 15
sec at 95˚C, 1 min at 60˚C. The melting curve was performed with 1 cycle of 20 sec at 95˚C, 15
sec 50˚C, and 98˚C with a temperature ramp of 0.1˚C/sec. Each sample was analyzed in dupli-
cate, and all measurements included the determination of the standards and a no-template
negative control, in which the DNA was substituted by water. We run a standard curve in each
PCR, constructed using ten-fold serial dilutions of synthesized oligonucleotides. For the
RPLP0 PCR we used the RPLP0 PCR product as standard, and the export values from the stan-
dard curves were diploid genome copies/reaction. The standard for telomere PCR is an oligo-
mer containing only the telomeric DNA tandem repeats (TTAGGG repeated 14 times), and
the export values from the standard curves were kbp of telomeric sequences/reaction. The
kbp/reaction value was divided by the diploid genome copy number/reaction to calculate the
aTL in kbp per human diploid genome, and then divided by the 92 telomeres present in a
human genome to inform the aTL in kbp per telomere. To evaluate the reliability of the assay
we calculated the intra and inter-CV, and they were sufficiently low for the RPLPO PCR (0.6%
and 3.9%, respectively) and for the telomere PCR (1.6% and 10.4%, respectively).
Statistical evaluation
Statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA).
We used one way-ANOVA and Bonferroni post-hoc test to compare biochemical, clinical and
anthropometric characteristics between groups. In agreement with the Central Limit Theorem,
due to the number of included patients, these variables were treated as normally distributed.
Linear regression was performed to evaluate the relationship between aTL and age for the gen-
eral population. The analysis of aTL in the groups MHNO, MHO and MSO, was performed by
multiple linear regression considering the groups as ordinal variable, since each group shows a
worse metabolic condition than the previous one; and the study of dummy variables to compare
the aTL between every pair of groups. In this analysis, the age-squared, pack-years smoked and
physical activity were used as covariates, as they were associated with aTL. The same analysis
was performed to evaluate the relationship between the aTL and the number of components of
MetS. A p value below 0.05 was considered as statistically significant.
Results
The overall population consisted of 400 women with a mean age of 46.76 years (SD = 15.47;
range: 18–86 years). Taking into account biochemical, clinical and anthropometric measure-
ments, we observed that 49.0% of the cohort (n = 196) were MHNO, 10.5% (n = 42) MHO and
25.5% (n = 102) MSO. The remaining 15.0% of the cohort (n = 60) did not display the charac-
teristics of any group, thus they were not included for this part of the study. All the variables
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analyzed showed significant differences among the three groups (Table 1). The post-hoc analy-
sis between MHNO and MHO, among which the only difference is the presence of obesity,
showed differences in the parameters related to body weight: BMI and waist circumference.
They also showed differences in SBP, DBP and hs-CRP. The other components of MetS (FPG,
TG and HDL-C), FSI and HOMA showed no differences between MHNO and MHO. On the
other hand, when we compared MHO with MSO women, similar values in BMI and hs-CRP
were observed, but they differ in every component of MetS (waist circumference, FPG,
HDL-C, TG, SBP and DBP), as expected considering that both groups are of obese individuals
and the difference between them are the presence of MetS. The MSO group also showed signif-
icantly higher values in the HOMA and FSI compared to MHO group. The comparison
between MHNO and MSO groups showed differences in all the biochemical-clinical parame-
ters analyzed. We also found significant differences in age when comparing the three groups,
where the MSO group presented significantly higher age than the other two groups.
The analysis of aTL showed a median value of 12.95 kbp (range: 1.57–72.12 kbp) for the
general population. The relationship between aTL and age was evaluated and a significant
shortening of aTL with age progression was observed in the general population (p = 0.001; r =
-0.12; 95% CI r = -0.20 / -0.05) (Fig 1).
Table 1. Characteristics of the population grouped according to the metabolic condition.
Groups Statistical
comparison
Test post-hoc
MHNO MHO MSO MHNO vs MHO MHO vs MSO MHNO vs MSO
M ± SD M ± SD M ± SD P MD 95% CI
MD
p MD 95% CI
MD
p MD 95% CI
MD
p
n 196 42 102
Age
(years)
42 ± 15 44 ± 15 51 ± 14 < 0.001 -1.94 -7.91/
4.02
NS -7.04 -13.47/-
0.6
0.027 -8.98 -13.26/-
4.69
<
0.001
BMI (kg
m-2)
24.52 ± 2.95 35.33 ± 6.65 36.94 ± 6.17 < 0.001 -10.82 -12.73/-
8.91
<
0.001
-1.61 -3.67/0.45 NS -12.43 -13.80/-
11.06
<
0.001
WC (cm) 86 ± 9 106 ± 10 112 ± 11 < 0.001 -19.53 -23.61/-
15.45
<
0.001
-5.97 -10.37/-
1.56
0.004 -25.49 -28.43/-
22.56
<
0.001
FPG (mg
dl-1)
89 ± 10 90 ± 8 115 ± 49 < 0.001 -1.37 -12.86/
10.12
NS -24.55 -36.94/-
12.16
<
0.001
-25.92 -34.17/-
17.67
<
0.001
FSI (mcU
ml-1)
9.95 ± 7.44 12.91 ± 7.99 19.01 ± 15.99 < 0.001 -2.96 -7.39/
1.47
NS -6.10 -10.87/-
1.33
0.007 -9.06 -12.24/-
5.88
<
0.001
HOMA 2.23 ± 1.79 2.88 ± 1.79 5.53 ± 6.2 < 0.001 -0.65 -2.17/
0.87
NS -2.65 -4.29/-
1.01
<
0.001
-3.31 -4.40/-
2.21
<
0.001
HDL-C
(mg dl-1)
57 ± 13 55 ± 12 47 ± 12 < 0.001 2.37 -2.95/
7.69
NS 7.97 2.23/
13.71
0.003 10.34 6.52/
14.16
<
0.001
TG (mg
dl-1)
97 ± 42 92 ± 36 166 ± 97 < 0.001 4.59 -21.44/
30.62
NS -73.99 -102.05/-
45.93
<
0.001
-69.40 -88.09/-
50.71
<
0.001
SBP
(mmHg)
111 ± 19 121 ± 20 137 ± 21 < 0.001 -9.64 -17.64/-
1.65
0.012 -15.45 -24.07/-
6.83
<
0.001
-25.09 -30.83/-
19.35
<
0.001
DBP
(mmHg)
69 ± 12 75 ± 14 83 ± 11 < 0.001 -6.11 -10.92/-
1.29
0.007 -8.13 -13.31/-
2.94
0.001 -14.23 -17.69/-
10.77
<
0.001
hs-CRP
(mg l-1)
2.01 ± 2.14 3.18 ± 2.60 3.89 ± 2.57 < 0.001 -1.17 -2.23/-
0.12
0.024 -0.70 -1.85/0.44 NS -1.88 -2.62/-
1.14
<
0.001
Statistical evaluation: One way-ANOVA and Bonferroni post-hoc test.
MHNO: Metabolically Healthy Non-obese individuals; MHO: Metabolically Healthy Obese individuals; MSO: Obese individual with Metabolic Syndrome; M:
mean; SD: standard deviation; MD: means difference; 95% CI MD: 95% confidence interval of the means difference; BMI: Body mass index; WC: Waist
circumference; FPG: fasting plasma glucose; FSI: Fasting serum insulin; HOMA: Homoeostasis Model Assessment; HDL-C: high-density lipoprotein
cholesterol; TG: triglycerides; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: High-Sensitive C reactive protein; NS: not significant.
https://doi.org/10.1371/journal.pone.0174945.t001
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The median aTL was 14.26 kpb (range: 2.66–72.12 kpb) for MHNO, 14.11 kpb (range: 2.83–
60.38 kpb) for MHO, and 12.51 kpb (range: 1.57–64.39 kpb) for MSO individuals. Although the
median aTL tend to decrease as the metabolic condition worsens, it did not archive statistical
significance (p = 0.054; r = -1.43; 95% CI r = -2.88 / 0.02). The comparison of aTL among
groups showed that MSO had significantly shorter aTL than MHNO (p = 0.036; r = -3.13; 95%
CI r = -6.06 / -0.21), and MHO (p = 0.033; r = -4.63; 95% CI r = -8.89 / -0.37), but we found no
differences in aTL between MHNO and MHO (p = 0.456, r = -1.50; 95% CI r = -5.44 / 2.45)
(Fig 2A), indicating that aTL was influenced by the presence of MetS, but it was not affected by
the presence of obesity. All these results were performed with age-squared, tobacco consump-
tion and physical activity corrections. Thus, in order to evaluate the relationship between aTL
and the number of MetS components, we regrouped the population according to the number of
components of the MetS.
From the total of 400 women of the general population, 18.5% (n = 74) had no components
of MetS (group 0), 20.0% (n = 80) showed one component (group 1), 21.0% (n = 84) had two
components (group 2) and 40.5% (n = 162) showed three or more components (group MetS).
All biochemical-clinical characteristics analyzed showed significant differences among the
four groups (Table 2). In the post-hoc comparison the group with MetS differed from all other
groups without MetS (0, 1 and 2) in all variables analyzed.
Fig 1. Telomere length as a function of age for the general population. Statistical evaluation: Linear regression. Mean (─) and standard
deviation (-). aTL: Absolute telomere length.
https://doi.org/10.1371/journal.pone.0174945.g001
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The median aTL was 16.35 kpb (range: 2.86–64.99 kpb) for individuals with no components
of MetS, 13.24 kpb (range: 2.66–72.12 kpb) for individuals with one component, 12.75 kpb
(range: 2.66–51.57 kpb) for individuals with two components, and 11.91 kpb (range: 1.57–
64.39 kpb) for individuals with MetS. It can be seen that the median aTL is shorter with the
presence of MetS abnormalities, and that it becomes shorter with the increase in the number
of components of the MetS. In addition, we observed statistically significant association
between aTL and the number of components of MetS with age-square, tobacco consumption
and physical activity corrections (p< 0.001; r = -2.06; 95% CI r = -3.13 / -0.99) (Fig 2B). The
comparison between groups showed that individual with no components of MetS (group 0)
had aTL significantly longer than the other groups (0 vs 1: p = 0.007, r = -4.87, 95% CI r =
-8.42 / -1.31; 0 vs 2: p = 0.006, r = -5.15, 95% CI r = -8.85 / -1.46; 0 vs MetS: p< 0.001, r =
-7.06, 95% CI r = -10.44 / -3.69), with no differences between groups 1, 2 and MetS (1 vs MetS:
p = 0.173, r = -2.19, 95% CI r = -5.35 / 0.97; 2 vs MetS: p = 0.208, r = -1.91, 95% CI r = -4.88 /
1.06; 1 vs 2: p = 0.874, r = -0.29, 95% CI r = -3.82 / 3.25), reinforcing the idea that the presence
of at least one of the MetS components is associated with a shorter aTL.
Discussion
This is the first description about aTL in a population of MHO patients compared to MSO and
MHNO individuals. To our knowledge, this is the first report showing that MHO group had
no differences in aTL with respect to the MHNO group, but it shows significant differences
with respect to the MSO group.
Fig 2. Telomere length according to the metabolic condition (A) and according to the number of components of metabolic syndrome (B).
Statistical evaluation: Multiple linear regression and the study of dummy variables. Covariates: age, pack-years smoked and physical activity. aTL: Absolute
telomere length; MHNO: Metabolically Healthy Non-obese individuals; MHO: Metabolically Healthy Obese individuals; MSO: Obese individual with
Metabolic Syndrome; MetS: Metabolic Syndrome (individual with three or more components).
https://doi.org/10.1371/journal.pone.0174945.g002
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Table 2. Characteristics of the population grouped according to the Metabolic Syndrome number of components.
A MetS number of components Statistical comparison
0 1 2 MetS
M ± SD M ± SD M ± SD M ± SD P
n 74 80 84 162
Age (years) 35 ± 10 39 ± 15 51 ± 14 53 ± 14 < 0.001
BMI (kg m-2) 24.23 ± 3.06 26.31 ± 5.34 28.48 ± 6.86 33.12 ± 7.14 < 0.001
WC (cm) 84 ± 10 89 ± 11 95 ± 13 105 ± 14 < 0.001
FPG (mg dl-1) 86 ± 8 89 ± 8 92 ± 11 112 ± 44 < 0.001
FSI (mcU ml-1) 10.14 ± 7.93 9.11 ± 5.88 12.07 ± 8.54 16.38 ± 13.96 < 0.001
HOMA 2.18 ± 1.81 2.02 ± 1.34 2.80 ± 2.08 4.68 ± 5.25 < 0.001
HDL-C (mg dl-1) 64 ± 11 52 ± 12 54 ± 14 47 ± 13 < 0.001
TG (mg dl-1) 78 ± 28 89 ± 31 117 ± 50 170 ± 97 < 0.001
SBP (mmHg) 103 ± 12 113 ± 20 122 ± 19 135 ± 21 < 0.001
DBP (mmHg) 65 ± 8 70 ± 12 76 ± 13 81 ± 12 < 0.001
hs-CRP (mg l-1) 1.70 ± 1.69 2.43 ± 2.49 2.43 ± 2.44 3.73 ± 2.48 < 0.001
B Test post-hoc
0 vs 1 0 vs 2 1 vs 2
MD 95% CI MD p MD 95% CI MD p MD 95% CI MD p
Age (years) -4.02 -9.84/1.81 NS -15.43 -21.19/-9.67 < 0.001 -11.42 -17.06/-5.77 < 0.001
BMI (kg m-2) -2.08 -4.72/0.55 NS -4.25 -6.85/-1.64 < 0.001 -2.17 -4.72/0.38 NS
WC (cm) -4.35 -9.57/0.87 NS -10.68 -15.84/-5.52 < 0.001 -6.33 -11.39/-1.28 0.006
FPG (mg dl-1) -3.43 -15.69/8.83 NS -6.42 -18.53/5.7 NS -2.98 -14.86/8.89 NS
FSI (mcU ml-1) 1.03 -3.56/5.61 NS -1.94 -6.47/2.6 NS -2.96 -7.37/1.45 NS
HOMA 0.16 -1.4/1.71 NS -0.62 -2.16/0.92 NS -0.78 -2.27/0.72 NS
HDL-C (mg dl-1) 11.50 6.16/16.84 < 0.001 9.46 4.18/14.74 < 0.001 -2.04 -7.2/3.11 NS
TG (mg dl-1) -10.76 -40.1/18.58 NS -38.81 -67.81/-9.8 0.003 -28.05 -56.47/0.37 NS
SBP (mmHg) -9.71 -17.79/-1.63 0.009 -19.27 -27.25/-11.28 < 0.001 -9.56 -17.38/-1.73 0.008
DBP (mmHg) -5.13 -10.04/-0.21 0.036 -10.84 -15.69/-5.98 < 0.001 -5.71 -10.47/-0.96 0.009
hs-CRP (mg l-1) -0.73 -1.78/0.33 NS -0.73 -1.77/0.3 NS 0.00 -1.05/1.04 NS
C Test post-hoc
0 vs MetS 1 vs MetS 2 vs MetS
MD 95% CI MD p MD 95% CI MD p MD 95% CI MD p
Age (years) -17.89 -22.96/-12.82 < 0.001 -13.87 -18.81/-8.93 < 0.001 -2.45 -7.31/2.41 NS
BMI (kg m-2) -8.90 -11.19/-6.6 < 0.001 -6.82 -9.05/-4.58 < 0.001 -4.65 -6.84/-2.45 < 0.001
WC (cm) -20.51 -25.06/-15.97 < 0.001 -16.16 -20.59/-11.73 < 0.001 -9.83 -14.18/-5.47 < 0.001
FPG (mg dl-1) -25.83 -36.51/-15.16 < 0.001 -22.40 -32.8/-12 < 0.001 -19.42 -29.65/-9.19 < 0.001
FSI (mcU ml-1) -6.25 -10.25/-2.25 < 0.001 -7.28 -11.13/-3.42 < 0.001 -4.31 -8.11/-0.52 0.017
HOMA -2.51 -3.87/-1.15 < 0.001 -2.66 -3.98/-1.35 < 0.001 -1.89 -3.18/-0.6 0.001
HDL-C (mg dl-1) 16.55 11.90/21.21 < 0.001 5.05 0.54/9.56 0.019 7.10 2.65/11.53 < 0.001
TG (mg dl-1) -91.59 -117.14/-66.04 < 0.001 -80.84 -105.72/-55.95 < 0.001 -52.79 -77.27/-28.3 < 0.001
SBP (mmHg) -31.64 -38.66/-24.61 < 0.001 -21.93 -28.77/-15.08 < 0.001 -12.37 -19.1/-5.64 < 0.001
DBP (mmHg) -16.50 -20.77/-12.23 < 0.001 -11.37 -15.53/-7.21 < 0.001 -5.66 -9.75/-1.57 0.002
hs-CRP (mg l-1) -2.03 -2.94/-1.12 < 0.001 -1.30 -2.22/-0.38 0.001 -1.30 -2.19/-0.41 0.001
Statistical evaluation: One way-ANOVA (A) and Bonferroni post-hoc test (B-C).
MetS: Metabolic Syndrome; M: mean; SD: standard deviation; MD: means difference; 95% CI MD: 95% confidence interval of the means difference; BMI:
Body mass index; WC: Waist circumference; FPG: fasting plasma glucose; FSI: Fasting serum insulin; HOMA: Homoeostasis Model Assessment; HDL-C:
high-density lipoprotein cholesterol; TG: triglycerides; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: High-Sensitive C reactive
protein; NS: not significant.
https://doi.org/10.1371/journal.pone.0174945.t002
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MHO group would be defined as a subgroup of obese patients with an intermediate phenotype
between MHNO and MSO individuals. In this way, when we compared MHO and MSO groups
we found that both had similar BMI, but they differ in every component of MetS. The difference
in waist circumference demonstrates the importance of central obesity in the development of
MetS. Actually, it is accepted that visceral and ectopic fat content has been associated with a
decrease in insulin sensitivity, which could play an important role in the development of meta-
bolic complications and increase risk of CVD. In that sense, we observed that although MHO
individuals have large quantities of fat mass, they might present remarkably normal to high levels
of insulin sensitivity. This could be due to MHO individuals which show 49% less visceral adipose
tissue (as measured from computed tomography) than at risk subjects with the MetS [28]. On the
other hand, when we compared MHNO and MHO they showed differences in BMI, waist cir-
cumference and blood pressure, but not in the other components of MetS. We could see that
MHO had similar CRP than MSO, as recently found in Brazilian population [29]. Also, when we
evaluated the insulin resistance, we found that MHO had significantly lower HOMA index com-
pared to MSO patients, and that MHO and MHNO did not differ with respect to insulin sensibil-
ity. Similar results have been published in metabolically healthy peripherally obese [30].
When MHO was followed up during longitudinal studies in order to investigate the cardiovas-
cular risk and mortality, results showed that MHO group is a clinical entity in between healthy
non-obese individuals and MetS individuals. A 7-years prospective study found that MHO subjects
did not have an increased risk for CVD or all-cause mortality compared with healthy non-obese
individuals [31]. However, another study with a follow-up period of 7.4 years revealed that obese
participants without MetS had higher risk of major cardiovascular events compared with metaboli-
cally healthy non-obese subjects but less than unhealthy metabolic non-obese individuals [32]. A
recent meta-analysis that evaluated participants for all-cause mortality and/or CVD showed an
increased risk for CVD in MHO individuals compared to metabolically healthy normal weight
individuals (OR [Odds ratio] = 1.24, 95% CI = 1.02–1.55), but fewer than obese unhealthy individ-
uals (OR = 2.65; 95% CI = 2.18–3.12) [33]. Furthermore, the patients with coronary artery disease
who presented MetS had shorter TL than patients without MetS [34].
Our molecular analysis showed that aTL in MHO group is similar to that observed in
MHNO and larger than in MSO individuals, supporting the finding that those patients have a
better metabolic behavior than MetS individuals.
Another finding of our work was that the aTL is dependent upon the presence of metabolic
abnormalities. Thus, we could associate shorter aTL with the raise in the number of MetS com-
ponents, supporting a relationship between telomere shortening and the metabolic severity. In
agreement with our results, a recent report [35] found that shorter TL was related with a higher
number of MetS abnormalities representing a more severe metabolic profile. Although this
association, found at baseline of the study, was reduced over two to six years follow up, shorter
baseline TL was still significantly associated with unfavorable scores of most MetS compo-
nents. In addition, Njajou et al [36] published similar findings, where a seven years follow up
was associated with smaller increases in BMI and body fat in those individuals who presented
longer TL. Rehkopf et al [37] in a large nationally representative U.S. sample did not find an
association between MetS and shorter TL. They did not report the prevalence of MetS in their
population and not stratify the individuals in accordance to the variables of MetS, as we per-
formed in our study. Although we found shorter aTL in MSO and an association with the
number of MetS components, like Rehkopf we could not associate MetS with shorter aTL. In
this sense, we had not found association between TL and the individual components of MetS
(data not shown). Anyway, we must consider genetics, ethnics, demographics, feeding and
behaviors differences between both populations that may interfere the relationship between
TL and MetS.
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Several issues may influence the TL; some of them are not modifiable such as age, inheri-
tance, gender and ethnicity, among the most important ones. On the other hand, there are mod-
ifiable clinical variables that may determine the TL, such as high FPG, increase BMI and waist
circumference, high TG, reduced HDL-C, smoking, physical activity, and diet. In this respect,
different studies showed the relationship between TL and metabolic abnormalities [38–40]. In
our study, we could associate the number of metabolic alterations with aTL. In this respect,
molecular mechanism such as inflammation and oxidative damage could lead to short telo-
meres as a consequence of a worsened metabolic state as we demonstrated in this work [41].
Interestingly, the increasing in abdominal adiposity was found to be accompanied by shorter
TL, in the same way we found that MHO had a waist circumference lowest than MSO [42]. In
this regards, recently an Editorial has been published about MHO which includes definition,
metabolic outcomes, molecular genetics findings and therapeutic interventions [43]. This paper
claims the need about longitudinal trials in individuals who are MHO at baseline and determine
the development of the typical metabolic complications of obesity and the molecular genetics
mechanisms contributing toward its development. Beyond whether MHO is or not a clinical
entity, we could associate the shorter aTL to the increased presence of metabolic disorders,
emphasizing the importance of its clinical management to prevent cardiovascular disease.
Martin-Ruiz et al [44] published that the variation of the TL and the amount of methodo-
logical differences between laboratories is large and it has been demonstrated a huge inter-lab-
oratory variation even for relative TL following internal normalization. In general, it must be
considered that the same reference range for TL cannot be applied by all laboratories. So, TL
measurement of an individual or a group of individuals could only be useful as a risk indicator
if reference values were measured by the same laboratory using the same protocols.
In conclusion, we are showing for the first time that aTL in MHO women is similar to that
in MHNO women, and longer than that observed in MSO women, suggesting its importance
in the interpretation of physiopathology and treatment of this subtype of obesity [45]. Our
work has some limitations: (i) it was carried out only in women, (ii) we studied the aLT aver-
age of all white blood cells in peripheral circulation without controlling for cell type, (iii) oxi-
dative stress molecular markers were not determined. Nevertheless, our report indicates that:
(i) some metabolic conditions such as MHO, is not associated with shorter aTL; and (ii)
shorter aTL is related to MetS and with the increased number of metabolic abnormalities, rep-
resenting a more severe metabolic profile and finally that the shortening of the aTL throughout
life is less pronounced in individuals with normal weight and without metabolic abnormalities.
Although some findings are consistent with a role for TL in the etiology of CVD and MetS, is
unclear the exact relationship between them [46]. We thought that the TL shortens as a conse-
quence of multiple types of biochemical stressors and may represent an index of several
known risk factors. In this way, our study may contribute to this matter.
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